Treatment Outcome, Relapse Patterns, And Prognostic Factors Of Adult Medulloblastoma Patients

s lai,junsheng cheng,chonggang wang,yongsheng chen,syyen kuo
DOI: https://doi.org/10.1016/j.ijrobp.2012.07.685
2012-01-01
Abstract:In the present study, we investigated the clinical outcome and prognostic factors of adult medulloblastoma patients receiving multimodality treatment. We retrospectively reviewed the clinical manifestations, tumor characteristics, treatment variables, relapse patterns, and clinical outcome (disease-free survival [DFS], and overall survival [OS]) of all adult patients with medulloblastoma pathologically diagnosed at our institution between 1983 and 2009. Sixteen (80%) of 20 patients received gross total resection and four (20%) of 20 patients received subtotal tumor resection (6 women and 14 men; median age: 22 years). Adjuvant chemotherapy was administered to six patients. Craniospinal irradiation (CSI) was given postoperatively using a 60 Co teletherapy machine or 6-MV linear accelerator or tomotherapy. The craniospinal axis received a median of 30 Gy/1.6–2 Gy/d (range: 23.4-39.6 Gy), and the tumor was boosted to receive a total median dose of 50 Gy (range: 50-55.25 Gy). After a median follow up of 36 months, the 3-year DFS and OS rates for all patients were 50% and 55%, respectively. In univariate analysis, Karnofsky Performance Scale (KPS) > 70 (p = 0.037), neurologic symptoms duration 30 days (p = 0.019), lateral tumor location (p = 0.016), standard risk patients (p = 0.029), no hydrocephalus (p = 0.035), radiation therapy (RT) treatment field (CSI+ brain boost) (p = 0.024), and CSI dose ≥ 30 Gy (p = 0.032) were significantly associated with better DFS. Standard risk patients (p = 0.045), RT treatment field (CSI+ brain boost) (p = 0.038), and CSI dose ≥ 30 Gy (p = 0.041) were also significantly associated with better OS. The combined modality treatment results in a favorable outcome for adult patients with medulloblastoma. Further investigation of the disease-related prognostic factors, radiation-related factors, and the role of systemic chemotherapy in this group of patients is needed.
What problem does this paper attempt to address?